This study tested the capability of a single 42-pg dose of inhaled salmeterol xinafoate, a long-acting P2-agonist, to 
. The 12 and 18 h after sal¬ meterol; others (eg, subjects 2, 9, and 10) were still protected beyond 18 h. Subject 5 (one of the less re¬ active subjects in the screening S02/exercise challenge, with a 16% FEVi decrease) showed no meaningful response to SO2 in experimental exposures, and there¬ fore no measureable benefit from salmeterol. Subjects 3 and 6 also were noticeably less responsive in the S02/placebo study than in screening, whereas subjects 9 and 10 were more responsive. All subjects except subject 5 '20,21 
